MondegarAI
Octagon Capital Advisors LP

Q4 2024 · 13F-HR

Octagon Capital Advisors LPholdings as filed

Filed 2025-02-14 · accession 0001839435-25-000002

$607.7M
Reported value
33
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$96.0M15.8%3,006,980CommonSOLE
04272N102AVBPARRIVENT BIOPHARMA INC$54.9M9.03%2,059,387CommonSOLE
252828108DNTHDIANTHUS THERAPEUTICS INC$46.0M7.57%2,110,167CommonSOLE
152309100CNTACENTESSA PHARMACEUTICALS PLC$33.4M5.49%1,993,052CommonSOLE
925050106VRNAVERONA PHARMA PLC$26.5M4.37%571,264CommonSOLE
67080N101NUVBNUVATION BIO INC$24.5M4.03%9,202,907CommonSOLE
457669307INSMINSMED INC$22.9M3.77%332,000CommonSOLE
19240Q201COGTCOGENT BIOSCIENCES INC$21.6M3.55%2,763,000CommonSOLE
80706P103SRRKSCHOLAR ROCK HLDG CORP$21.1M3.47%488,000CommonSOLE
60255C885BRD1EURMIND MEDICINE MINDMED INC$21.0M3.46%3,018,000CommonSOLE
67576A100OCULOCULAR THERAPEUTIX INC$20.7M3.41%2,425,000CommonSOLE
877619106TSHATAYSHA GENE THERAPIES INC$18.1M2.97%10,450,000CommonSOLE
457669307INSMINSMED INC$17.3M2.84%250,000CALLSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$16.7M2.74%870,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$16.6M2.73%18,350,000CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$15.7M2.59%668,000CommonSOLE
N69605108PHVSPHARVARIS N V$14.9M2.45%778,000CommonSOLE
21833P301CRBPCORBUS PHARMACEUTICALS HLDGS$13.2M2.17%1,115,000CommonSOLE
N5749R1002GHMERUS N V$13.0M2.13%308,000CommonSOLE
29479A108ERASERASCA INC$12.9M2.12%5,136,795CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$12.1M1.99%441,600CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$12.0M1.97%904,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$11.6M1.91%1,370,000CommonSOLE
90466Y103UNICYCIVE THERAPEUTICS INC$7.9M1.31%10,000,000CommonSOLE
75915K309RGLSREGULUS THERAPEUTICS INC$7.7M1.26%4,848,802CommonSOLE
46489V302CATXPERSPECTIVE THERAPEUTICS INC$7.4M1.21%2,304,752CommonSOLE
64135M105NGNENEUROGENE INC$6.9M1.14%303,000CommonSOLE
019818202ALLOVIR INC$4.7M0.78%11,215,000CommonSOLE
002120202ATYRATYR PHARMA INC$3.3M0.54%900,000CommonSOLE
G4444H101BBOTHELIX ACQUISITION CORP II$2.6M0.43%250,000CommonSOLE
152309100CNTACENTESSA PHARMACEUTICALS PLC$2.5M0.42%152,000PUTSOLE
59045L106MERSANA THERAPEUTICS INC$1.4M0.23%992,000CommonSOLE
67080N119NUVB/WSNUVATION BIO INC$830,8140.14%312,336CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.